Sofia Zetterstrand

888 total citations
14 papers, 657 citations indexed

About

Sofia Zetterstrand is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Physiology. According to data from OpenAlex, Sofia Zetterstrand has authored 14 papers receiving a total of 657 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Cardiology and Cardiovascular Medicine, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Physiology. Recurrent topics in Sofia Zetterstrand's work include Gastroesophageal reflux and treatments (3 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (3 papers) and Respiratory and Cough-Related Research (3 papers). Sofia Zetterstrand is often cited by papers focused on Gastroesophageal reflux and treatments (3 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (3 papers) and Respiratory and Cough-Related Research (3 papers). Sofia Zetterstrand collaborates with scholars based in Sweden, Canada and United Kingdom. Sofia Zetterstrand's co-authors include Hertzel C. Gerstein, Karl Swedberg, Salim Yusuf, John J.V. McMurray, Christopher B. Granger, Eric L. Michelson, Marc A. Pfeffer, Bertil Olofsson, Scott D. Solomon and Colette E. Jackson and has published in prestigious journals such as The Lancet, JAMA and Diabetes Care.

In The Last Decade

Sofia Zetterstrand

14 papers receiving 639 citations

Peers

Countries citing papers authored by Sofia Zetterstrand

Since Specialization

Citations

This map shows the geographic impact of Sofia Zetterstrand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sofia Zetterstrand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sofia Zetterstrand more than expected).

Fields of papers citing papers by Sofia Zetterstrand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sofia Zetterstrand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sofia Zetterstrand. The network helps show where Sofia Zetterstrand may publish in the future.

Co-authorship network of co-authors of Sofia Zetterstrand

This figure shows the co-authorship network connecting the top 25 collaborators of Sofia Zetterstrand. A scholar is included among the top collaborators of Sofia Zetterstrand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sofia Zetterstrand. Sofia Zetterstrand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Title	Journal	Authors	Indexed citations
1	Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn’s disease	BMC Gastroenterology	Silvio Danese, Elizabeth A. Duncan et al.	11
2	Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease	JAMA	Robert A. Wise, Kenneth R. Chapman et al.	18
3	Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease: Pooled Analysis of Two Randomized Trials	American Journal of Respiratory and Critical Care Medicine	Fernando J. Martínez, Klaus F. Rabe et al.	54
4	Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE2SPOND): A Randomized Clinical Trial	American Journal of Respiratory and Critical Care Medicine	Fernando J. Martínez, Klaus F. Rabe et al.	93
5	Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain	Scandinavian Journal of Gastroenterology	Anne Lund Krarup, Lars Ny et al.	102
6	Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists	Thrombosis Research	Michael Wolzt, Ulf G. Eriksson et al.	6
7	Long-Term Outcome after Treatment of Hydrocephalus in Children	Pediatric Neurosurgery	Sofia Zetterstrand, Daniel Nilsson et al.	33
8	Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy	Thrombosis Research	Gregory Y.H. Lip, Lars Hvilsted Rasmussen et al.	23
9	Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837	European Journal of Clinical Pharmacology	Maria Svensson, Sofia Zetterstrand et al.	12
10	Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis – results from the EXPO study	Alimentary Pharmacology & Therapeutics	Joachim Labenz, David Armstrong et al.	7
11	Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis ‐ results from the maintenance phase of the EXPO study	Alimentary Pharmacology & Therapeutics	Joachim Labenz, David Armstrong et al.	9
12	Albuminuria in chronic heart failure: prevalence and prognostic importance	The Lancet	Colette E. Jackson, Scott D. Solomon et al.	224
13	A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension	Blood Pressure	Björn W. Karlson, Sofia Zetterstrand et al.	12
14	Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program	Diabetes Care	David Preiss, Sofia Zetterstrand et al.	53

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact